B. Riley Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $270
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani upgrades Madrigal Pharmaceuticals (MDGL) from Sell to Neutral and increases the price target from $155 to $270.
March 15, 2024 | 11:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Madrigal Pharmaceuticals was upgraded from Sell to Neutral by B. Riley Securities, with a price target increase from $155 to $270.
The upgrade from Sell to Neutral by a reputable analyst, along with a significant increase in the price target, suggests a positive reassessment of Madrigal Pharmaceuticals' prospects. This is likely to be viewed positively by the market, potentially leading to a short-term increase in MDGL's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100